search button

LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor‑κB pathways

  • Authors:
    • Yan Yang
    • Xiaoli Yang
    • Lin Li
    • Gangyi Yang
    • Xuhong Ouyang
    • Jialin Xiang
    • Tao Zhang
    • Xun Min

  • View Affiliations

  • Published online on: March 13, 2019     https://doi.org/10.3892/or.2019.7058
  • Pages: 3005-3014
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

LAG1 longevity assurance homolog 2 (LASS2) is a candidate biomarker in cancer that is dysregulated in various types of tumor, potentially affecting cell growth, invasion and migration. Although its effects on liver cancer metastasis and invasion have been reported, specific phenotypic studies and potential molecular mechanisms have not been completely elucidated in hepatoblastoma (HB). In the present study, the effect of LASS2 on the proliferation, apoptosis and cell cycle of HepG2 HB cells was assessed, and the underlying mechanisms were investigated. The human LASS2 coding sequence was inserted into an adenovirus vector and transduced into HepG2 cells. It was determined that the overexpression of LASS2 inhibited HepG2 cell viability and proliferation, as determined by cell counting kit‑8 and colony formation assays, and induced apoptosis by increasing reactive oxygen species, reducing mitochondrial membrane potential and inducing intracellular Ca2+ overload. In addition, the overexpression of LASS2 induced G0/G1 cell cycle arrest through modulating the expression of cell cycle regulatory proteins, including p27, cyclin D1 and cyclin‑dependent kinase 4. Immunofluorescence was used to determine that nuclear factor (NF)‑κB p‑p65 was primarily expressed in the cytoplasm rather than in the nucleus; western blot analysis demonstrated that LASS2 downregulated the expression of NF‑κB p‑p65 relative to its inactive form in HepG2 cells. These findings suggest that LASS2 inhibits proliferation and induces apoptosis in HepG2 HB cells through the mitochondrial apoptotic, NF‑κB and cell cycle signaling pathways.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 41 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Yang X, Li L, Yang G, Ouyang X, Xiang J, Zhang T and Min X: LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor‑κB pathways. Oncol Rep 41: 3005-3014, 2019
APA
Yang, Y., Yang, X., Li, L., Yang, G., Ouyang, X., Xiang, J. ... Min, X. (2019). LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor‑κB pathways. Oncology Reports, 41, 3005-3014. https://doi.org/10.3892/or.2019.7058
MLA
Yang, Y., Yang, X., Li, L., Yang, G., Ouyang, X., Xiang, J., Zhang, T., Min, X."LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor‑κB pathways". Oncology Reports 41.5 (2019): 3005-3014.
Chicago
Yang, Y., Yang, X., Li, L., Yang, G., Ouyang, X., Xiang, J., Zhang, T., Min, X."LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor‑κB pathways". Oncology Reports 41, no. 5 (2019): 3005-3014. https://doi.org/10.3892/or.2019.7058